PHOENIX, AZ -- (Marketwired) -- 10/29/13 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that the Company will release its financial results for the third quarter of 2013 on Tuesday, November 12, 2013, before the U.S. financial markets open.
Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 11:00 a.m. Eastern Standard Time.
Interested parties may participate in the conference call by dialing 888-329-8893 (U.S.) or 719-325-2244 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for two weeks by dialing 888-203-1112 (U.S.) or 719-457-0820 (International) and entering conference call ID number 5992606. A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.